Some new weight-loss drugs that work on two hormone receptors at once seem to help people lose a lot of weight and also improve liver health in those with fatty liver disease, based on early studies.

1

Pro

0

Against

Evidence from Studies

Supporting (1)

1

Community contributions welcome

1

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

Narrative Review

Animal

2025 Dec

The study looked at drugs that activate two receptors—glucagon and GLP-1—and found they helped people lose weight and improved liver health, just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

Score: 1

DOI: 10.1111/dom.70148

Similar Assertions

Blocking the glucagon signal in people with type 2 diabetes might cause weight gain, more fat in the liver, and higher blood fat levels — suggesting this hormone helps control how the body uses energy and fat.

1

0

74%

Blocking the hormone glucagon with drugs might actually make things worse for people — causing weight gain, higher blood pressure, and more liver fat.

0

74%

Medications that mimic a gut hormone called GLP-1 can make people feel less hungry, eat less food, and lose body fat over time.

0

70%

A drug called retatrutide helps people lose a lot of weight—sometimes over 70 pounds—by targeting certain hormones, but it works so well that it can cause unexpected health problems.

61

57

70%